Cosmo’s Partner RedHill announces approval of Talicia® for the treatment of H. Pylori in adults in the USA
Cosmo Pharmaceuticals N.V. today informs that its partner RedHill Biopharma (NASDAQ: RDHL, Tel-Aviv Stock Exchange: RDHL) today announced that the U.S. Food and Drug Administration (FDA) has approved Talicia® (omeprazole magnesium1 10.3 mg, amoxicillin 250 mg and rifabutin 12.5 mg) delayed-release capsules for the treatment of Helicobacter pylori (H. pylori) infection in adults.